医生对REMS计划药物风险沟通的理解与认知研究
Physician Understanding and Perceptions of Risk Communication Related to Drugs Covered by Risk Evaluation and Mitigation Strategy Programs
作者：Heidi Zakoul、Carol Cosenza、Su Been Lee、Winta Tekle、Ariel Freedman、Shruti Belitkar、Gita A. Toyserkani、Kate Heinrich Oswell、Cynthia LaCivita、Gerald J. Dal Pan、Aaron S. Kesselheim、Ameet Sarpatwari
单位：Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.；Center for Survey Research, University of Massachusetts Boston, Boston, Massachusetts, USA.；Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA.
摘要
发表于《Pharmacoepidemiology and Drug Safety》2026年10月刊（第35卷第10期），研究探讨医生对FDA风险管理计划（REMS）覆盖药物的风险沟通方式的理解程度与认知态度，为优化处方环节的风险传递提供实证依据。
AI 主编 · 推荐理由推荐理由
REMS是美国药品上市后风险管理核心工具，直接影响处方行为与患者用药安全。该研究揭示医生群体对风险信息的理解缺口，为我国药品风险沟通机制设计与药物警戒培训提供参考。